CRON Cronos Group Inc.

bullish track record → $2.73 -0.03 (-1.1%)
Get emailed when CRON changes direction
Mkt Cap $1B 52wk $1.73 - $3.43 Earnings 2026-05-07 48d ago
Est. revisions: -66.7%
Factor Model (net -3.4)

Factor Model

net -3.4 6.4 / 10
Est. Revisions
-1.0
Insider Activity
+0.0
Momentum
+0.0
Analyst Rev.
-1.0
Narrative Gap
-0.5

Two Buy ratings lock in scaling thesis for Cronos

Watch: Quarterly cash burn and gross margin trends will make or break the bull case. Revenue growth alone won't satisfy skeptics; the company must demonstrate it can actually lever its lean cost base and expand profitability as sales rise.

Cronos has attracted back-to-back analyst coverage with dual Buy ratings in late January and February 2026, signaling institutional conviction in a turnaround grounded in unit economics rather than sector tailwinds. TD Securities initiated on February 24 with a C$4.50 price target, citing iconic brands and a lean cost structure primed for profitability expansion as revenue scales. Canaccord followed on January 27 with a C$4.25 target, framing the CanAdelaar acquisition and Cronos Growing Company expansion as catalysts for vertical integration and international reach across Canada and Israel.

Two independent firms arriving at the same conviction — Buy ratings within weeks — is rare and carries weight. The convergence on scalable margins rather than cannabis macro upside suggests analysts see operational discipline, not sector hype, as the story. This positions Cronos to compound gains if execution matches the model's promise.

Evidence

Fundamentals & Data ▾
Cronos Group Inc. Healthcare · Drug Manufacturers - Specialty & Generic
Mkt Cap
$1B
Beta
1.21
52w Range
$1.73 - $3.43
Short Interest
3.8M 1.97%
Days to Cover
3.7 -0%
Technicals downtrend
from 52w Hi
-1.1%
1w return
+6.2%
Insiders
mixed 0B / 0S
EPS Estimate
$0.01 -66.7% 30d 0up / 1dn
Analyst Target
$2 $2 - $2
Options P/C
0.00
Fund Convergence
strong Citadel, Renaissance, Two Sigma
Financials
Revenue
$45M +47% YoY
FCF
$10M
Gross Margin
36%
Op Margin
-14%
Momentum: accelerating
Top Holders
Citadel $7M
Renaissance $5M
Two Sigma
Recent Filings & Data
insider trade 38
net selling
9 insiders · 38 transactions (30d)
Recent transactions
Shlimak (Anna) · other
Shlimak (Anna) · other
Shlimak (Anna) · exercise · $24,808
Buggy (Shannon) · other
Buggy (Shannon) · exercise · $23,005
Doucet (Terrence Gregory Joseph) · other
Doucet (Terrence Gregory Joseph) · exercise · $30,788
Gorenstein (Michael Ryan) · other
Gorenstein (Michael Ryan) · exercise · $319,265
Jacobson (Jeffrey David) · other
Jacobson (Jeffrey David) · exercise · $56,380
Shlimak (Anna) · exercise · $40,885
Weigensberg (Aaron Arye) · other
Buggy (Shannon) · other
Buggy (Shannon) · exercise · $27,051
Buggy (Shannon) · other
Buggy (Shannon) · exercise · $33,199
Doucet (Terrence Gregory Joseph) · other
Doucet (Terrence Gregory Joseph) · exercise · $32,544
Gorenstein (Michael Ryan) · other
Gorenstein (Michael Ryan) · exercise · $331,319
Jacobson (Jeffrey David) · other
Jacobson (Jeffrey David) · exercise · $65,804
Shlimak (Anna) · other
Shlimak (Anna) · exercise · $48,683
Weigensberg (Aaron Arye) · other
Gorenstein (Michael Ryan) · other
Gorenstein (Michael Ryan) · exercise · $212,556
Weigensberg (Aaron Arye) · other
Kenost (Jared) · other
Wilson (Lloyd Anderson) · other
Doucet (Terrence Gregory Joseph) · other
Doucet (Terrence Gregory Joseph) · other
Wagner (Aaron Shmuel) · other
Weigensberg (Aaron Arye) · other
Wagner (Aaron Shmuel) · other
Wagner (Aaron Shmuel) · other
Weigensberg (Aaron Arye) · other
1 signals · latest 48d ago

Get alerted when CRON changes direction

We'll email you when our AI detects a shift — reversals, insider clusters, filing red flags.